



### Investment Objective

The Leverage Shares -3x Short Biotechnology ETP Securities seeks to track the -3x Short Biotechnology Investment Strategy, which is designed to provide -3x the daily return of iShares Biotechnology ETF stock, adjusted to reflect the fees and inherent costs and revenues of shorting. It holds the short positions in the underlying iShares Biotechnology ETF stock and resulting cash balances.

For example, if iShares Biotechnology ETF rises by 1% over a day, then the ETP will fall by 3%, excluding fees. However, if iShares Biotechnology ETF falls by 1% over a day, then the ETP will rise by 3%, excluding fees.

### Key Features

- Opportunity to magnify returns in one simple trade.
- Liquid. Trades like an equity on exchange, with multiple market makers (MMs).
- You cannot lose more than the amount invested, and an intraday rebalance mechanism is designed to cushion the largest intra-day falls.
- Simple to trade, no need for futures, no need to use margin accounts.
- Transparent structure with full ownership of the underlying assets, so credit risk effectively negated.
- Is independent and managed by industry experts.


### Key Risks

- Investing in Short and Leveraged ETPs is only suitable for sophisticated traders who understand leverage, daily rebalancing and compounded daily returns.
- Investors can lose the full value of their initial investment (but not more).
- Losses are magnified due to the nature of leveraged returns. Therefore, Short and Leveraged ETPs are only suitable for investors willing to take a high level of risk.
- Daily compounding may result in returns which an investor may not expect if the investor has not fully understood how a Leverage Shares ETP works.
- Due to daily rebalancing and compounding, ETP returns measured over periods longer than one day may differ from the returns of the underlying stock multiplied by the leverage factor.
- Only use these ETPs if you can monitor your positions daily or during the day.
- Please see the 'Risks Factors' section of the Prospectus for a more detailed discussion of the potential risks associated with an investment in this product.

### PRODUCT INFORMATION

Product Name	Leverage Shares -3x Short Biotechnology ETP
Underlying Security	iShares Biotechnology ETF
Leverage Factor	-3
Replication	Physical (Underlying Assets Owned)
Base Currency	USD
ISIN	XS2399370472
Structure / Legal Form	ETP / Debt Security
Countries Available	United Kingdom, Italy, Germany, France, Spain, Netherlands, Ireland, Poland and Belgium
Issuer	Leverage Shares PLC
Trustee	Apex Corporate Trustees (UK) Limited
Stock Lender	Interactive Brokers LLC
Interest on Cash Balances	Fed Funds Effective (Overnight Rate) - 1.5%
Annual Management Fee	0.75%
SIPP/ISA Eligible	Yes
Sec 871(m)	Not Applicable (see FAQs)

### Risk and Reward Profile



N.B. This diagram is not a UCITS synthetic risk & reward indicator and is enclosed for information purposes only

Investors should refer to the Prospectus ([www.leverageshares.com](http://www.leverageshares.com)) for a more complete description of the product, service providers and relevant regulatory factors.

COUNTRY	EXCHANGE	BASE CURRENCY	TRADING CURRENCY	EXCHANGE CODE	ISIN	SEDOL	BBG	RIC	LISTING DATE
UK	London Stock Exchange	USD	USD	IBBS	XS2399370472	BNDKHP1	IBBS LN	IBBS.L	14/12/2021
UK	London Stock Exchange	USD	GBx	SIBB	XS2399370472	BNDKLW6	SIBB LN	SIBB.L	14/12/2021
UK	London Stock Exchange	USD	EUR	SIBE	XS2399370472	BNDKKH4	SIBE LN	SIBE.L	14/12/2021
Netherlands	Euronext Amsterdam	USD	EUR	SIBB	XS2399370472		SIBB NA	SIBB.AS	16/12/2021
France	Euronext Paris	USD	EUR	IBBS	XS2399370472		IBBS FP	IBBS.PA	16/12/2021

## Contact Information

Contact us at via email at [info@leverageshares.com](mailto:info@leverageshares.com) or on Twitter at @LeverageShares. More information on Leverage Shares can we found online at [www.leverageshares.com](http://www.leverageshares.com).

## Disclaimer

Leverage Shares ETPs are only intended for sophisticated traders who understand the associated risks and are able to monitor their positions on an intraday basis. Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Base Prospectus and the Leverage Shares educational materials carefully before considering the ETPs.

## No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

## No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

## Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs offering daily leveraged or daily short exposures ("Leveraged ETPs") are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Short and leveraged exchange-traded products are only intended for investors who understand the risks involved in investing in a product with short and/or leveraged exposure and who intend to invest on a short-term basis. Any investment in short and/or leveraged products should be monitored on a daily basis to ensure consistency with your investment strategy. You should understand that investments in short and/or leveraged exchange-traded products held for a period of longer than one day may not provide returns equivalent to the return from the relevant unleveraged investment multiplied by the relevant leverage factor.

Potential losses in short and/or leveraged exchange-traded products may be magnified in comparison to investments that do not incorporate these strategies. Please refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in short and/or leveraged exchange-traded products. You should consult an independent investment adviser prior to making an investment in short and/or leveraged exchange-traded products in order to determine its suitability to your circumstances.

## Prospectus

Investors should refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in the securities offered by the Issuer.

The Prospectus has been approved by the Central Bank of Ireland as competent authority under Regulation (EU) 2017/1129 and the Financial Conduct Authority as competent authority under the United Kingdom's version of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

The Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the prospectus of the Issuer has been drawn up in accordance with Article 25 of Regulation (EU) 2017/1129.

The prospectus (and any supplements thereto) of the Issuer has been passported from Ireland into Italy (Commissione Nazionale per la Società e la Borsa), Germany (Bundesanstalt für Finanzdienstleistungsaufsicht), France (Autorité des Marchés Financiers), Spain (Comisión Nacional del Mercado de Valores), the Netherlands (the Autoriteit Financiële Markten), Poland (Komisja Nadzoru Finansowego) and Belgium (Belgian Financial Services and Markets Authority).

Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.

